Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) received a $69.00 price objective from Cantor Fitzgerald in a note issued to investors on Thursday. The firm currently has a “buy” rating on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 15.58% from the company’s previous close.
Several other equities analysts also recently weighed in on AERI. Mizuho reiterated a “buy” rating and set a $87.00 target price on shares of Aerie Pharmaceuticals in a research report on Thursday, November 9th. Canaccord Genuity set a $65.00 target price on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, August 8th. HC Wainwright set a $69.00 target price on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. Stifel Nicolaus reiterated a “buy” rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a research report on Friday, July 28th. Finally, BidaskClub upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $71.43.
Aerie Pharmaceuticals (NASDAQ AERI) traded up $0.40 on Thursday, hitting $59.70. The company had a trading volume of 337,211 shares, compared to its average volume of 524,391. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78. Aerie Pharmaceuticals has a fifty-two week low of $35.20 and a fifty-two week high of $66.25.
ILLEGAL ACTIVITY NOTICE: This report was first published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://transcriptdaily.com/2017/11/16/cantor-fitzgerald-analysts-give-aerie-pharmaceuticals-inc-aeri-a-69-00-price-target.html.
Several institutional investors have recently added to or reduced their stakes in the company. Aperio Group LLC raised its holdings in shares of Aerie Pharmaceuticals by 4.7% in the 2nd quarter. Aperio Group LLC now owns 4,914 shares of the company’s stock worth $258,000 after purchasing an additional 219 shares during the period. Ameritas Investment Partners Inc. raised its holdings in shares of Aerie Pharmaceuticals by 11.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,665 shares of the company’s stock worth $140,000 after purchasing an additional 275 shares during the period. Legal & General Group Plc raised its holdings in shares of Aerie Pharmaceuticals by 7.4% in the 2nd quarter. Legal & General Group Plc now owns 7,534 shares of the company’s stock worth $396,000 after purchasing an additional 519 shares during the period. Bamco Inc. NY raised its holdings in shares of Aerie Pharmaceuticals by 13.4% in the 2nd quarter. Bamco Inc. NY now owns 5,511 shares of the company’s stock worth $290,000 after purchasing an additional 653 shares during the period. Finally, Chartwell Investment Partners LLC raised its holdings in shares of Aerie Pharmaceuticals by 3.2% in the 3rd quarter. Chartwell Investment Partners LLC now owns 25,591 shares of the company’s stock worth $1,243,000 after purchasing an additional 791 shares during the period. Institutional investors own 95.71% of the company’s stock.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.